The available data suggest that treatment with DPP-4 inhibitors may have a mild beneficial effect on NAFLD, probably mediated by the increase in GLP-1 concentrations after blocking DPP-4 activity. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.